[Form 4] Seer, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rubric Capital Management LP, an investment adviser headquartered in New York, and its managing member David Rosen jointly filed Amendment No. 2 to Schedule 13G on 07 July 2025 regarding their holdings in Ovid Therapeutics Inc. (OVID).

• Beneficial ownership: 478,533 common shares.
• Ownership percentage: 0.67 % of the 71,109,514 shares outstanding as of 19 May 2025 (per the issuer’s latest proxy).
• Voting & disposition rights: 0 shares sole voting/dispositive power; 478,533 shares shared voting and shared dispositive power.
• Reporting persons: Rubric Capital (investment adviser) and David Rosen (individual, control person).
• Filing trigger date: 30 June 2025; the position is now below the 5 % threshold, leading to a “Ownership of 5 percent or Less” disclosure.
• Certification: Securities held in the ordinary course and not for the purpose of influencing control.

The filing is informational, confirming a modest (<1 %) stake by Rubric Capital without indicating any intent to alter the company’s control or strategy.

Insights

Financial Analyst

TL;DR – Rubric discloses a 0.67 % passive stake; immaterial for OVID valuation.

This Schedule 13G/A signals that Rubric Capital and David Rosen collectively own fewer than 1 % of Ovid Therapeutics’ outstanding shares. The filing classifies the position as passive under Rule 13d-1 and includes the standard certification that the shares are not held to influence control. Because the stake is well below the 5 % threshold, it implies limited ability to affect governance or trading dynamics. No purchase or sale prices, cost basis, or prior ownership figures are provided, so transaction directionality cannot be assessed. Overall, the disclosure is neutral for investors: it neither strengthens institutional sponsorship meaningfully nor raises governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gulyani Meeta

(Last) (First) (Middle)

C/O SEER, INC.

3800 BRIDGE PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Seer, Inc. [ SEER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/07/2025		A		20,500(1)	A	$0	107,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.18	07/07/2025		A		30,500		(2)	07/07/2035	Class A Common Stock	30,500	$0	30,500	D

Explanation of Responses:

1. The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 7, 2026 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

2. Shares subject to the option vest on the earlier of (i) July 7, 2026 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

	/s/ David Horn, by power of attorney	07/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many OVID shares does Rubric Capital currently own?

Rubric Capital and David Rosen report 478,533 Ovid Therapeutics common shares.

What percentage of OVID’s outstanding stock does this represent?

The holding equals 0.67 % of the 71,109,514 shares outstanding as of 19 May 2025.

Is Rubric Capital’s stake considered passive or active?

The Schedule 13G/A is filed under the passive ownership provisions; the filer certifies no intent to influence control.

Did Rubric Capital report any sole voting or dispositive power?

No. Sole voting and dispositive power are both 0; all 478,533 shares are held with shared power.

Why was this amendment filed on 07 July 2025?

The amendment reflects a reportable event dated 30 June 2025, likely the point when ownership details required an update.